Results
Filtros
Proposal to regulate cannabis cultivation is taken off Anvisa's meeting agenda
Decision postpones vote on new rules for cultivating low-THC varieties; new date for analysis not yet defined
Request for cannabis-based medicine without registration at Anvisa must be judged by the Federal Justice
STJ decision reinforces federal competence for actions involving unregistered drugs at the regulatory agency
Request for cannabis-based medicine without registration at Anvisa must be judged by the Federal Court
STJ decision reinforces federal jurisdiction for actions involving unregistered drugs at the regulatory agency
Anvisa Nominees' Hearing Scheduled in Senate
Social Affairs Committee to analyze four names for leadership positions in health agencies
Anvisa may vote on rules for national cultivation and control of cannabis this Wednesday (13)
Change may authorize cultivation by companies under strict control, with a limit of 0.3% THC; measure complies with a decision from the Superior Court of Justice (STJ) related to cultivation regulation.
Anvisa prohibits mushroom products sold by company that markets 18,000 units per month
Agency determined the prohibition of manufacturing, marketing, and use of mushroom-based supplements produced by Mush Mush Club Ltda.
Anvisa concludes public consultation on new regulation of Cannabis products
Deadline for submitting contributions to the proposal for the revision of RDC 327/2019 ended this Monday (2). Participation exceeded 7,000 forms
Anvisa to hold public hearing on regulatory framework for herbal medicines
Event will address rules that directly impact the herbal medicine sector and cannabis-based products; participation is open to the public.
Anvisa removes the revision of RDC 327/2019 from the Collegiate Board meeting agenda
Update of the RDC included in the Regulatory Agenda 2024-2025 is expected for next year
Lula's nominee for director-president of Anvisa awaits Senate confirmation hearing
Other names have been nominated; the positions in question are either vacant or with mandates nearing expiration
Anvisa discusses review of regulation of medicinal cannabis products
Public consultation proposal for the review of RDC No. 327/2019 will be evaluated by the Collegiate Board on December 19, 2024
Regulation of Cannabis Products for Medicinal Purposes Enters Anvisa's Regulatory Agenda 2024-2025
Review of the Brazilian Pharmacopoeia collegiates is also included in the Agenda
Anvisa announces mandatory information in SNGPC for 2025
Anvisa informs that, in 2025, the inclusion of data in the SNGPC will be mandatory. Pharmacy professionals have until December 31 to test the tool and clarify doubts
Leading cannabis market company expects release of new products by Anvisa in 2024
Data was disclosed by Close Up Farma, a company specialized in pharmaceutical auditing.
Controversial Authorization: Council asserts that biomedical professionals are able to prescribe cannabis, but Anvisa questions competence
07/24/2023Resolution No. 365 of the Federal Council of Biomedicine, which authorizes the prescription of traditional herbal products based on cannabidiol by biomedical professionals, clashes with resolutions of the health agency
Anvisa's Ordinance 344 Mixes Apples and Oranges When It Comes to Hemp
06/03/2022The lack of information still causes the properties of hemp to be confused with those of cannabis, especially when discussing psychoactive effects, which do not occur when we talk about hemp. But this confusion can further delay
Anvisa completes 23 years: a timeline about the agency and medicinal cannabis
01/26/2022On the anniversary of the National Health Surveillance Agency (Anvisa), learn about the evolution of the medicinal use of cannabis over the 23 years since the agency was created
New Anvisa directors move forward for Senate confirmation hearing
Social Affairs Committee confirms Safatle, Cerqueira, and Cardoso's names, in a moment of important reforms at the agency
UFLA integrates group presenting document to Anvisa on cannabis in scientific research and therapeutic use
Letter brings together experts from across the country and includes UFLA participation
Univali is authorized by Anvisa to perform analyses of Cannabis products
New authorization expands the university's scope in Reblas and reinforces the quality control of plant derivatives in the national market